Takeda’s Julie Kim argues that Trump’s idea to match drug prices to that of other countries could cost the industry up to $1 ...

The cell engineering company, co-founded by oncologist and writer Siddhartha Mukherjee, does not see a path forward for its ...

Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision ...

Year-over-year BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities ...

Gilead will construct three new facilities in the U.S., while upgrading three others. The company claims the investment will ...

The UCSF professor and frequent YouTube poster has criticized COVID-19 vaccine mandates as well as the accelerated approval ...

The independent experts will meet on May 22 to discuss updates to the COVID-19 vaccine for the upcoming season.

After more than a month of speculation over how the FDA will rule on Novavax’s application for an updated formulation of its ...

In this episode of Denatured BioSpace's head of insights Lori Ellis discusses the public health consequences of vaccine ...

The biopharma job market likely won’t turn around until 2026, according to two industry experts. Both cited a need for more ...

The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...

Yes, according to leading vaccine physician Paul Offit, who denounced the new placebo-controlled trial requirements for ...